首頁 > 市場調查報告書 > 製藥

感染疾病

抗真菌藥物市場規模、佔有率和成長分析（按藥物類別、適應症、劑型、分銷管道和地區分類）—產業預測（2026-2033 年）

市場調查報告書

商品編碼

1896015

抗真菌藥物市場規模、佔有率和成長分析（按藥物類別、適應症、劑型、分銷管道和地區分類）—產業預測（2026-2033 年）

Antifungal Drugs Market Size, Share, and Growth Analysis, By Drug Class (Azoles, Echinocandins), By Indication (Dermatophytosis, Aspergillosis), By Dosage Form, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月15日 | 出版商:

SkyQuest | 英文 214 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，抗真菌藥物市場規模將達到 155.4 億美元，到 2025 年將達到 161.5 億美元，到 2033 年將達到 219.3 億美元，預測期（2026-2033 年）的複合年成長率為 3.9%。

真菌感染疾病（例如麴菌症和念珠菌症）發病率的不斷上升是推動抗真菌藥物市場成長的主要因素。這些感染疾病包括全身性和表淺性兩種類型，可涉及皮膚、眼睛、口腔和陰道等部位。抗真菌藥物，尤其是具有殺菌活性的藥物，在治療多種疾病（包括足癬、體癬和真菌性腦膜炎）方面發揮重要作用。醫院感染的增加和感染疾病的流行也促進了市場擴張。真菌感染疾病是一項重大的公共衛生挑戰，尤其對免疫力缺乏的人群（包括愛滋病患者）更是如此。真菌疾病的這種上升趨勢凸顯了對有效抗真菌療法的巨大需求，為市場提供了強勁成長的潛力。

抗真菌藥物市場促進因素

真菌感染疾病和院內感染發病率的不斷上升是推動抗真菌藥物市場成長的主要因素。抗真菌藥物在治療因接觸醫療機構中受污染或潮濕環境而引起的全身性和表淺性性行為感染方面發揮重要作用。此外，公眾和醫療專業人員對真菌感染疾病的認知不斷提高，也顯著推動了對這些藥物的需求。隨著越來越多的人和醫療機構意識到真菌感染疾病的影響，抗真菌藥物市場有望在這種日益成長的認知和對有效治療方案的需求下取得顯著進展。

限制抗真菌藥物市場的因素

抗真菌藥物市場面臨的一大挑戰是真菌感染的漏診率居高不下，這主要是由於醫護人員和公眾對真菌感染疾病的認知不足所造成的。這種認知不足會導致患者治療延誤，並面臨治療方案選擇不足的問題。為了解決這個問題，亟需進行全面的教育活動，以提高公眾意識並改善診斷方法。此外，病患與醫護人員之間溝通不良和理解不足也是導致漏診和治療不足的原因之一。提高這方面的知識水平對於最佳化患者預後和更有效地治療真菌感染疾病至關重要。

抗真菌藥物市場趨勢

抗真菌藥物市場呈現顯著上升趨勢，主要得益於藥物研發的不斷進步。隨著研究人員探索新的藥物製劑、創新的給藥系統和標靶治療，更有效的治療方案的潛力正在不斷擴大。這種發展不僅改善了患者的治療效果，也為專注於研發的製藥公司創造了盈利的利潤。透過專注於創新解決方案，這些公司能夠滿足日益成長的先進抗真菌療法需求，尤其是在真菌感染疾病發病率上升和對傳統治療方法的抗藥性日益增強的情況下。因此，市場呈現出成長跡象，而新型抗真菌藥物在其中發揮關鍵作用。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭格局

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市集活動
主要企業市佔率（2025 年）

主要企業簡介

Pfizer Inc.（US）
Gilead Sciences, Inc.（US）
Astellas Pharma Inc.（Japan）
F. Hoffmann-La Roche AG（Switzerland）
Sanofi SA（France）
Bayer AG（Germany）
Cipla Limited（India）
Hetero Labs Limited（India）
Hikma Pharmaceuticals PLC（UK）
Galderma SA（Switzerland）
Aurobindo Pharma（India）
Cipla USA Inc.（US）
Sandoz（a Novartis division）（Switzerland）
Fresenius Kabi AG（Germany）
Reddy's Laboratories Ltd.（India）
Zydus Cadila Healthcare Ltd.（India）
Eton Pharmaceuticals, Inc.（US）
Pyxis Oncology（US）
Incyte Corporation（US）

簡介目錄

Product Code: SQMIG35I2358

Antifungal Drugs Market size was valued at USD 15.54 Billion in 2024 and is poised to grow from USD 16.15 Billion in 2025 to USD 21.93 Billion by 2033, growing at a CAGR of 3.9% during the forecast period (2026-2033).

The growing incidence of fungal infections such as aspergillosis and candidiasis is significantly driving the antifungal drugs market. These infections encompass both systemic and superficial types, affecting areas like skin, eyes, mouth, and vagina. Antifungal medications, particularly those with fungicidal properties, are key in addressing a wide array of conditions, including athlete's foot, ringworm, and fungal meningitis. The rise in hospital-acquired infections and the prevalence of infectious diseases further contribute to market expansion. Fungal diseases present a substantial public health challenge, particularly for individuals with compromised immune systems, including those living with AIDS. This increasing burden of fungal illnesses underlines the critical demand for effective antifungal therapies, positioning the market for robust growth potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Antifungal Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Antifungal Drugs Market Segments Analysis

Global Antifungal Drugs Market is segmented by Drug Class, Indication, Dosage Form, Distribution Channel, and region. Based on Drug Class, the market is segmented into Azoles, Echinocandins, Polyenes, Allylamines, and Others. Based on Indication, the market is segmented into Dermatophytosis, Aspergillosis, Candidiasis, and Others. Based on Dosage Form, the market is segmented into Oral Drugs, Ointments, Powders, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retails Pharmacies, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Antifungal Drugs Market

The increasing incidence of fungal and hospital-acquired infections serves as a key factor propelling the growth of the antifungal drugs market. Antifungal medications play a crucial role in treating both systemic and superficial infections, which can arise from contact with contaminated environments in healthcare settings or from humid conditions. Additionally, the expanding awareness regarding fungal diseases among the general population and healthcare professionals is significantly driving the demand for these medications. As more individuals and medical providers recognize the impact of fungal infections, the antifungal drugs market is poised for substantial advancement in response to this heightened awareness and need for effective treatment options.

Restraints in the Antifungal Drugs Market

A significant challenge in the antifungal drugs market is the frequent underdiagnosis of fungal infections, stemming from limited awareness among healthcare professionals and the general population. This lack of recognition can result in delayed, inadequate treatment options for those affected. Addressing this issue underscores the need for comprehensive educational initiatives aimed at bolstering awareness and improving diagnostic practices. Additionally, miscommunication and insufficient understanding between patients and healthcare providers can contribute to the continued prevalence of underdiagnosis and undertreatment. Enhancing knowledge in this area is crucial for optimizing patient outcomes and moving towards more effective management of fungal infections.

Market Trends of the Antifungal Drugs Market

The antifungal drugs market is witnessing a significant upward trend driven by ongoing advancements in drug development. As researchers explore new drug formulations, innovative delivery systems, and targeted therapies, the potential for more effective treatments expands. This evolution not only enhances patient outcomes but also creates lucrative opportunities for pharmaceutical companies committed to research and development. By focusing on innovative solutions, these companies can meet the growing demand for advanced antifungal therapies, especially in response to the rising incidence of fungal infections and increased resistance to traditional treatments. Consequently, the market is poised for growth, with novel antifungal agents playing a pivotal role.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Case study Analysis
Regulatory Landscape
Top Investment Analysis
Key Success Factor
Degree of Competition
PESTEL Analysis
FDA Approved Antifungal Drugs List
Market Attractiveness Index, 2025

Antifungal Drugs Market by Drug Class

Market Overview
Azoles
- Fluconazole
- Voricanazole
- Posaconazole
- Clotrimazole
- Others
Echinocandins
- Caspofungin
- Micafungin
- Others
Polyenes
- Amphotericin B
- Others
Allylamines
- Terbinafine
- Naftifine
- Others
Others

Antifungal Drugs Market by Indication

Market Overview
Dermatophytosis
Aspergillosis
Candidiasis
Others

Antifungal Drugs Market by Dosage Form

Market Overview
Oral Drugs
Ointments
Powders
Others

Antifungal Drugs Market by Distribution Channel

Market Overview
Hospital Pharmacies
Retails Pharmacies
Others

Antifungal Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hetero Labs Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Galderma S.A. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla USA Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz (a Novartis division) (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius Kabi AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Cadila Healthcare Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eton Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pyxis Oncology (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments